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Objective: To evaluate the recognition of NS4B mimotope, as multiple antigen peptide
(MAP), by dengue antibodies presents in serum samples from patients with different
serotype infections.
Methods: A MAP containing mimotope sequence was synthesized and used to evaluate
the recognition of NS4B mimotope as MAP by a panel of 66 human sera from dengue
cases by an indirect ELISA assay.
Results: The MAP differentiated between sera from dengue viruses infected patients and
sera from healthy individuals and the best reactivity was shown by serum from dengue
type 3 virus patients. The recognition was more intense with serum from patients with
secondary infection.
Conclusions: The ﬁndings suggest the potential use of NS4B mimotope on the devel-
opment of a multi-epitope diagnostic tool. These results are important for further
immunogenicity studies.1. Introduction
Dengue viruses (DENV) belong to the family Flaviviridae,
and the genome encodes 3 structural proteins: the capsid (C),
precursor membrane (prM), envelope (E) and 7 non-structural
proteins (NS1–NS5). Robust antibody responses are generated
to 3 proteins: E, which contains 3 distinct domains, Ⅰ, Ⅱ, and Ⅲ
(potent neutralizing activity); prM, which augments infectivity
of poorly infectious immature virions; and NS1, which directs
complement-mediated lysis of infected cells [1]. Serological
studies in humans have suggested, that after a DENV
infection, people develop serum antibodies against some of the
non-structural proteins (NS1, NS3, NS5) [2]. However, few
studies have been carried out to characterize the immune
response to others non-structural proteins [3].
The advent of the phage-displayed peptide technology, in
which large, complex libraries of ﬁlamentous bacteriophage
bearing random peptide sequences on their coat proteins can begenerated and screened with antibodies, has provided a new
approach to identify previously unknown antigens and/or new
epitopes on already known antigens [4]. In this approach, phage-
displayed peptide libraries are screened with sera from patients
who have suffered a particular disease or pathological condition
to discover peptide epitopes that are speciﬁcally recognized by
patient's sera [5–7].
The present study extends previous results obtained with the
mimotope of the non-structural NS4B DENV protein. The NS4
protein is composed of two distinct domains: NS4A and NS4B
which may play a role in viral replication [8], however, the role
in humoral immunity of NS4B has been poorly studied.
Nevertheless, detection of antibody speciﬁc to puriﬁed
recombinant GST-NS4B antigen was reported in serum sam-
ples from dengue patients [9]. Here we evaluate the recognition
of NS4B mimotope as MAP by dengue antibodies in serum
samples from patients with different dengue serotype infections.
2. Materials and methods
2.1. Serum samples
All the serum specimens used in the study came from a hu-
man sera collection stored at −20 C. To obtain these sera, all
procedures followed were in accordance with the ethicalrticle under the CC BY-NC-ND license (http://
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tation (institutional and national) and with the Helsinki Decla-
ration of 1975, as revised in 2008 [Cuadernos de Bioe´tica (Bs
As) 2010; 15/16:289–348].
Sera collected from 66 dengue conﬁrmed adult patients and
stored at the Dengue Sera Bank of the Virology Department at
the ‘Pedro Kouri’ Tropical Medicine Institute of Havana in Cuba
were analyzed in this study. Dengue diagnostics was conﬁrmed
by virus isolation and identiﬁcation, RT-PCR and IgM-IgG
determination. Cases were classiﬁed in primary or secondary
infection according to anti-dengue IgG level [10,11]. Serum
samples were collected ﬁve to seven days or two months after
the onset of fever. Sera from healthy donors were obtained
from the Cuban National Blood Bank and used as a negative
control.
2.2. Synthetic peptides
Peptides consisting of the mimotope from NS4B DENV
protein, mimotope from E DENV protein (as positive control of
antigen) [12] and mimotopes from Hepatitis A virus (HAV) (as
negative control of antigen) [13] were synthesized at the
Synthetic Peptide Laboratory at the Center for Genetic
Engineering and Biotechnology (Havana City) (Table 1). The
peptides were named NS4B MAP, E peptide and MAP 46–56,
respectively.
2.3. Indirect ELISA-NS4 MAP and controls
Multi-well plates (Nunc Maxisorp F8, Life Technologies
Limited, Paisley, UK) were coated with 100 mL/well of NS4B
MAP: 5 mg/mL, E peptide: 20 mg/mL or MAP 46–56: 5 mg/mL
diluted in 0.05 M sodium carbonate buffer pH 9.6 (coating
buffer), and incubated overnight at 4 C. Plates were washed 3
times with phosphate buffered saline in 0.05% Tween 20 (PBS/
T) and blocked with skimmed milk (3% w/v) in PBS/T
(blocking solution) for 1 h at 37 C. Human serum samples
diluted in blocking solution (1:20, 100 mL/well) were added to
the plates and incubated 1 h at 37 C. After repeating the
washes, bound antibodies were detected with HRP-conjugated
anti-human IgG antibodies (Sigma–Aldrich, UK), H2O2 and o-
phenylenediamine dihydrochloride (Sigma). The reaction was
stopped with 0.1 M H2SO4. The absorbance at 492 nm was
measured by an automated ELISA reader. All samples were run
in duplicate and results were expressed as mean values of optical
density (OD) ratios.
Control ELISAs were run in parallel, in which the E peptide
and HAV MAP were used. Each ELISA was performed twice.
Positivity criteria: The formula ratio = P/N where P is the OD
obtained in the sample and N is the OD mean values obtained
with sera of healthy donors for the screening of the serum
sample with NS4B peptide was employed. A sample with a
ratio  2 was considered positive.Table 1
Sequence of mimotopes contained in synthetic antigens.
Peptide constructs Sequence
NS4B MAP (four arms) FERVPEGV
E peptide linear LGQSVGQDS
HAV MAP/46–56 (four arms) 46 SHSQLGPPVGPP
56 SHSVTKSLRVFGGPP2.4. Statistical analysis
The GraphPad Prism statistical software (San Diego, CA,
USA) was used. The Mann Whitney test was used to compare
the results of OD ratios obtained in each serotype and values of
P < 0.05 were considered signiﬁcant.
3. Results
To analyze the potential of NS4B mimotope as MAP to
behave as antigen, their ability to detect anti-DENV antibodies
was assessed. ELISA screening was performed with human sera
collected from dengue patients with NS4B MAP. The reactivity
of 30 serum samples from secondary cases to DENV-1 (n = 10),
DENV-3 (n = 10) and DENV-4 (n = 10) is shown in Figure 1.
Serum samples of DENV-2 infection were not available for the
study. The OD ratio values for DENV-3 were statistically sig-
niﬁcant when compared with DENV-1 (P = 0.03) and DENV-4
(P = 0.04).
Dengue antibodies from the studied samples were not
detected with MAP 46–56 used as control, demonstrating a
speciﬁc recognition of NS4B MAP by antibodies produced in
response to the natural dengue infection. Figure 1 shows the
results obtained with dengue 3 sera against MAP 46–56.
The unpaired sera of 48 patients from DENV-3 positive cases
(20 serum samples collected between ﬁve to seven days, and 28
collected after two months of fever onset) were used to compare
the response to NS4B antibodies by ELISA-NS4B MAP
(Figure 2). These patients were classiﬁed in primary or sec-
ondary type of infection. NS4B MAP was recognized strongly
by samples collected at ﬁve to seven days in secondary infection
(70%) and only 2 were positive in primary cases. Sera
collected  two months showed the highest percentage of
recognition in both primary (93%) and secondary cases (100%);
however, the OD ratios were lowest in relation with secondary
cases (samples ﬁve to seven days). A greater reactivity to E
peptide, used as positive control, was observed in sera collected
at the convalescent phase of illness (data not shown).Figure 1. ELISA reactivity of human sera to NS4B mimotope as MAP.
ELISA was performed using serum samples collected from conﬁrmed
DENV-1, DENV-3, DENV-4 patients. Results are expressed as OD ratio,
and are presented for individual samples (10 samples to each serotype).
MAP 46–56 was used as not related peptide (negative control). Values were
considered as positive when OD ratio  2.0 and is represented by the dotted
horizontal line.
Figure 2. Recognition of NS4B MAP of serum samples from patients with
primary (P 5–7 = 10 and P  2 m = 13) or secondary (S 5–7 = 10 and
S  2 m = 15) dengue 3 infections by an Indirect ELISA. Results are
expressed as OD ratio and are presented for individual samples.
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One of the advantages of the phage display technology is to
reduce complex protein antigens to small structured peptides that
retain immune recognition. Mimotopes can potentially serve as
lead compounds to develop low molecular weight substitutes of
the template protein for the development of diagnostic assays
[6,14]. This approach has been widely used in epitope mapping of
ﬂavivirus [15–18]. Recently, a mimotope of NS4B protein of
DENV-3 was obtained by screening a solid-phase 9mer
random peptide library using human immune sera. The selected
sequences mimic the binding properties of natural antigen epi-
topes [19].
In this study, we detected antibodies against DENV from
serum samples of dengue patients using the NS4B mimotope by
indirect ELISA. The mimotope was synthesized in the MAP
form, because the binding efﬁciency of an MAP is greater than
that of a single-chain peptide. Short synthetic peptides are usu-
ally ineffective antigens for solid phase immunoassays owing to
their poor ability to attach to solid surfaces. The multimeric
nature of MAP constructs have been found to overcome these
deﬁciencies and provide consistently reproducible results in
increased surface-binding properties and sensitivity of detection
[20]. The high reactivity with DENV-3 can be explained by the
fact that the NS4B mimotope was selected with an anti-dengue 3
sera [19]. These data correlate well with the results reported by
several authors who identiﬁed serotype speciﬁc epitopes using
the phage-displayed peptide library screening method [15–18,21].
The serum antibody responses are different following pri-
mary and secondary DENV infections. In secondary infections,
the stimulation of B-cell memory leads to a rapid rise in DENV-
speciﬁc IgG that is measurable even on the ﬁrst day of symp-
toms. Moreover DENV speciﬁc serum IgG titers are much
higher in secondary compared to primary infections [1]. Valdes
et al. [22] have demonstrated that the antibody response to
NS5 and NS3 proteins in acute-phase samples from secondary
cases is greater than in primary cases, including the intensity of
the reaction, due to the high levels of IgG antibodies in sec-
ondary cases. The present study conﬁrms these results, with the
presence of anti-NS4B antibodies in acute-phase samples from
secondary cases, using NS4B mimotope as MAP. Previously,
NS4B MAP was shown to induce robust humoral response in
mice and these antibodies were able to recognize NS4B protein,
which is produced in the ﬁrst step of viral replication [12]. On the
other hand, ‘in silico’ analysis predicted potential B-cell epitopeson the NS4B protein including the epitope mimic of NS4B [23].
These preliminary data support the usefulness of NS4B MAP to
detect antibodies to DENV in human sera suggesting that the
NS4B protein of dengue virus could be implicated in the
humoral response. Our ﬁndings suggest the potential use of
NS4B mimotope for the development of a multi-epitope diag-
nostic tool. These results are important for further immunoge-
nicity studies towards the evaluation of the mimotope as
experimental vaccine.
Conﬂict of interest statement
We declare that we have no conﬂict of interest.
Acknowledgments
The authors would like to thank Dr. Marta Romano for the
critical reading of the manuscript.
References
[1] Wahala WM, Silva AM. The human antibody response to dengue
virus infection. Viruses 2011; 3(12): 2374-2395.
[2] Mathew A, West K, Kalayanarooj S, Gibbons RV,
Srikiatkhachorn A, Green S, et al. B-cell responses during primary
and secondary dengue virus infections in humans. J Infect Dis
2011; 204(10): 1514-1522.
[3] Anandarao R, Swaminathan S, Khanna N. The identiﬁcation of
immunodominant linear epitopes of dengue type 2 virus capsid and
NS4a proteins using pin-bound peptides. Virus Res 2005; 112(1–2):
60-68.
[4] Paramasivam SK. Diagnostic and immunoprophylactic applica-
tions of synthetic peptides in veterinary microbiology. Microbiol
Res 2010; 1(1); http://dx.doi.org/10.4081/mr.2010.e1.
[5] Gazarian KG, Palacios-Rodriguez Y, Gazarian TG, Huerta L. HIV-
1 V3 loop crown epitope-focused mimotope selection by patient
serum from random phage display libraries: implications for the
epitope structural features. Mol Immunol 2013; 54(2): 148-156.
[6] Casey JL, Coley AM, Parisi K, Foley M. Peptide mimics selected
from immune sera using phage display technology can replace
native antigens in the diagnosis of Epstein-Barr virus infection.
Protein Eng Des Sel 2009; 22(2): 85-91.
[7] Houimel M, Dellagi K. Peptide mimotopes of rabies virus glyco-
protein with immunogenic activity. Vaccine 2009; 27(34): 4648-
4655.
[8] Miller S, Bartenschlager R. Subcellular localization and membrane
topology of the dengue virus type 2 non-structural protein 4B.
J Biol Chem 2006; 281: 8854-8863.
[9] La´zaro L, Mellado G, García J, Escobar A, Santos L, Gutie´rrez B,
et al. Analysis of antibody responses in human dengue patients
from the Mexican coast using recombinant antigens. Vector Borne
Zoonotic Dis 2008; 8(1): 69-79.
[10] Vazquez S, Cabezas S, Perez AB, Pupo M, Ruiz D, Calzada N,
et al. Kinetics of antibodies in sera, saliva, and urine samples from
adult patients with primary or secondary dengue 3 virus infections.
Int J Infect Dis 2007; 11(3): 256-262.
[11] Vazquez S, Acosta N, Ruiz D, Calzada N, Alvarez M,
Guzman MG. Immunoglobulin G antibody response in children
and adults with acute dengue 3 infection. J Virol Methods 2009;
159(1): 6-9.
[12] Amin N, Pupo M, Aguilar A, Camacho F, Alvarez M, Caballero Y,
et al. Immunogenicity of NS4b dengue 3 virus mimotope presented
to the immune system as multiple antigen peptide system. ISRN
Virol 2013; 2013(1); http://dx.doi.org/10.5402/2013/924057.
[13] Aguilar A, Camacho F, Martínez R, Huerta V, Garay H, Amin N,
et al. Study of peptide mimetics of hepatitis a virus conjugated to
keyhole limpet hemocyanin and as multiple antigen peptide sys-
tem. Int J Pept Res Ther 2014; 20(1): 33-42.
Nevis Amin et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(2): 130–133 133[14] Casey JL, Coley AM, Street G, Parisi K, Devine PL, Foley M.
Peptide mimotopes selected from a random peptide library for
diagnosis of Epstein-Barr virus infection. J Clin Microbiol 2006;
44(3): 764-771.
[15] Jiang L, Zhou JM, Yin Y, Fang DY, Tang YX, Jiang LF. Selection
and identiﬁcation of B-cell epitope on NS1 protein of dengue virus
type 2. Virus Res 2010; 150(1–2): 49-55.
[16] Chen YC, Huang HN, Lin CT, Chen YF, King CC, Wu HC.
Generation and characterization of monoclonal antibodies against
dengue virus type 1 for epitope mapping and serological detection
by epitope-based peptide antigens. Clin Vaccine Immunol 2007;
14(4): 404-411.
[17] Wu HC, Huang YL, Chao TT, Jan JT, Huang JL, Chiang HY, et al.
Identiﬁcation of B-cell epitope of dengue virus type 1 and its
application in diagnosis of patients. J Clin Microbiol 2001; 39(3):
977-982.
[18] Yao ZJ, Kao MC, Loh KC, Chung MC. A serotype-speciﬁc epitope
of dengue virus 1 identiﬁed by phage displayed random peptide
library. FEMS Microbiol Lett 1995; 127(1–2): 93-98.[19] Amin N, Aguilar A, Chamacho F, Vazquez Y, Pupo M,
Ramirez JC, et al. Identiﬁcation of dengue-speciﬁc B-cell epitopes
by phage-display random peptide library. Malays J Med Sci 2009;
16(4): 4-14.
[20] Tam JP, Zavala F. Multiple antigen peptide. A novel approach to
increase detection sensitivity of synthetic peptides in solid-phase
immunoassays. J Immunol Methods 1989; 124(1): 53-61.
[21] Tian Y, Chen W, Yang Y, Xu X, Zhang J, Wang J, et al. Identi-
ﬁcation of B cell epitopes of dengue virus 2 NS3 protein by
monoclonal antibody. Appl Microbiol Biotechnol 2013; 97(4):
1553-1560.
[22] Valdes K, Alvarez M, Pupo M, Vazquez S, Rodriguez R,
Guzman MG. Human dengue antibodies against structural and
nonstructural proteins. Clin Diagn Lab Immunol 2000; 7(5): 856-
857.
[23] Amin N, Reyes F, Calero R, Camacho F, Acosta A. T and B
epitope prediction of NS4B protein of dengue virus type 3. Vac-
cimonitor 2013; 22(3): 14-21.
